Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Aptevo Therapeutics (NASDAQ:APVO) announced a 1-for-37 reverse stock split effective December 3, 2024, with split-adjusted trading beginning December 4. The move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The split will reduce outstanding shares from approximately 18.5 million to 0.5 million. The reverse split will affect all issued shares, outstanding options, restricted stock units, warrants, and other securities. The company will round up fractional shares to the next whole share, while maintaining the current trading symbol 'APVO' and $0.001 par value per share.
Aptevo Therapeutics (NASDAQ:APVO) announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session and present at Cambridge Healthcare Institute's Pep Talk conference in January 2025. The presentation will showcase how Aptevo uses its ADAPTIR and ADAPTIR-FLEX platforms to accelerate cancer therapy development. Dr. Pavlik will demonstrate the company's modular biotherapeutic approach using clinical candidates Mipletamig and ALG.APV-527 as examples. The company currently has five compounds in clinical and preclinical development and plans to introduce a new molecule in early 2025.
Aptevo Therapeutics (NASDAQ:APVO) provided updates on its oncology pipeline focusing on bispecific antibodies for cancer treatment. The company highlighted two clinical programs: mipletamig for AML, which showed 90% reduction in leukemic blasts in its first Phase 1b/2 trial patient, and ALG.APV-527 for solid tumors, which demonstrated positive safety and 56% stable disease rate in Phase 1. The pipeline includes three preclinical candidates: APVO711, APVO603, and APVO442. The company expects the bispecifics market to grow by 44% through 2030 and plans to add another asset to its pipeline soon.
Aptevo Therapeutics (NASDAQ: APVO) reports promising early results from its RAINIER trial, where the first patient treated with mipletamig achieved a 90% reduction in leukemic blasts within 30 days. The trial evaluates mipletamig as a frontline therapy for Acute Myeloid Leukemia (AML) in combination with venetoclax and azacitidine. The triplet combination therapy targets AML through multiple mechanisms, potentially improving patient outcomes, particularly in elderly patients with treatment options. Previous trials demonstrated favorable safety profiles with manageable cytokine release syndrome levels, along with compelling response and durability of remission.
Aptevo Therapeutics (APVO) and Alligator Bioscience reported positive preliminary data from their Phase 1 trial of ALG.APV-527, a first-in-class bispecific antibody for solid tumors. The trial met key endpoints for safety, tolerability, and biological activity. 56% of evaluable patients (9/16) achieved stable disease, including a colon cancer patient stable for over 6 months and a breast cancer patient stable for over 11 months. Notably, no serious liver toxicity was observed, distinguishing it from other 4-1BB targeting treatments. Biomarker analysis confirmed immune activation in the tumor microenvironment, supporting the drug's mechanism of action.
Aptevo Therapeutics (NASDAQ:APVO) reported Q3 2024 financial results and clinical progress. The company initiated the mipletamig Phase 1b/2 'RAINIER' trial for frontline AML treatment and presented positive interim data for ALG.APV-527 in solid tumors, showing 60% of evaluable patients achieving stable disease. Financial results showed cash position of $7.8 million, reduced R&D expenses to $3.1 million (down from $3.9 million), and decreased G&A expenses to $2.1 million (down from $2.7 million). The company reported a net loss of $5.1 million ($0.48 per share) and raised $5.75 million through financings during the quarter.
Aptevo Therapeutics (NASDAQ:APVO) and Alligator Bioscience (ATORX) announced they will present new positive interim data from their Phase 1 trial of ALG.APV-527 at the SITC 2024 conference. The presentation will showcase results from the dose escalation phase evaluating ALG.APV-527 monotherapy in multiple solid tumor types. The poster presentation, titled 'Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 × 4-1BB bispecific antibody,' will demonstrate favorable safety and biological activity in patients with advanced solid tumors. The presentation is scheduled for November 8, 2024, at SITC 2024 in Houston, Texas.
Aptevo Therapeutics (Nasdaq: APVO) has closed a $3.0 million offering priced at-the-market under Nasdaq rules. The offering included 9,090,910 shares of common stock or pre-funded warrants, along with warrants to purchase up to 18,181,820 additional shares. The purchase price was $0.33 per share and associated warrant. Each share came with two Common Warrants, exercisable at $0.33 per share upon stockholder approval, expiring in five years.
Roth Capital Partners acted as the placement agent. Aptevo plans to use the net proceeds for clinical development of product candidates, working capital, and general corporate purposes. The company also amended previously issued warrants from July 2024, April 2024, and November 2023, reducing their exercise price to $0.33 per share, subject to stockholder approval.
Aptevo Therapeutics Inc. (NASDAQ:APVO) has announced a $3.0 million registered direct offering priced at-the-market under Nasdaq rules. The offering includes 9,090,910 shares of common stock or pre-funded warrants, along with warrants to purchase up to 18,181,820 additional shares. The purchase price is set at $0.33 per share and associated Common Warrant. Each share comes with two Common Warrants, exercisable at $0.33 per share upon stockholder approval, expiring in five years. The offering is expected to close around September 18, 2024. Roth Capital Partners is acting as the placement agent. Aptevo plans to use the net proceeds for clinical development of product candidates, working capital, and general corporate purposes. Additionally, the company will amend certain existing warrants from previous issuances, reducing their exercise price to $0.33 per share.
Aptevo Therapeutics (NASDAQ: APVO) and Alligator Bioscience (ATORX) announced positive interim data from their Phase 1 trial of ALG.APV-527, a bispecific antibody targeting 4-1BB and 5T4 for solid tumors. Key findings include:
- 60% of evaluable patients (9/15) achieved stable disease
- A breast cancer patient maintained stable disease for over 11 months
- Favorable safety, tolerability, and pharmacokinetics observed
- No maximum tolerated dose identified yet
- Biomarker analyses confirm biological activity
The trial is nearing full enrollment, with 18 patients included in the safety analysis. Results were presented at the ESMO Annual Congress on September 14, 2024.